133 related articles for article (PubMed ID: 12912947)
1. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers.
Hasegawa S; Miyoshi Y; Egawa C; Ishitobi M; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2003 Aug; 9(8):2992-7. PubMed ID: 12912947
[TBL] [Abstract][Full Text] [Related]
2. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
Galmarini CM; Treilleux I; Cardoso F; Bernard-Marty C; Durbecq V; Gancberg D; Bissery MC; Paesmans M; Larsimont D; Piccart MJ; Di Leo A; Dumontet C
Clin Cancer Res; 2008 Jul; 14(14):4511-6. PubMed ID: 18628466
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers.
Miyoshi Y; Kim SJ; Akazawa K; Kamigaki S; Ueda S; Yanagisawa T; Inoue T; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2004 Dec; 10(24):8163-9. PubMed ID: 15623590
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer.
Urano N; Fujiwara Y; Doki Y; Kim SJ; Miyoshi Y; Noguchi S; Miyata H; Takiguchi S; Yasuda T; Yano M; Monden M
Int J Oncol; 2006 Feb; 28(2):375-81. PubMed ID: 16391792
[TBL] [Abstract][Full Text] [Related]
5. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.
Miyoshi Y; Ando A; Takamura Y; Taguchi T; Tamaki Y; Noguchi S
Int J Cancer; 2002 Jan; 97(1):129-32. PubMed ID: 11774254
[TBL] [Abstract][Full Text] [Related]
6. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.
Bernard-Marty C; Treilleux I; Dumontet C; Cardoso F; Fellous A; Gancberg D; Bissery MC; Paesmans M; Larsimont D; Piccart MJ; Di Leo A
Clin Breast Cancer; 2002 Dec; 3(5):341-5. PubMed ID: 12533264
[TBL] [Abstract][Full Text] [Related]
7. Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel.
Shalli K; Brown I; Heys SD; Schofield AC
FASEB J; 2005 Aug; 19(10):1299-301. PubMed ID: 15946994
[TBL] [Abstract][Full Text] [Related]
8. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.
Ooe A; Kato K; Noguchi S
Breast Cancer Res Treat; 2007 Mar; 101(3):305-15. PubMed ID: 16821082
[TBL] [Abstract][Full Text] [Related]
9. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.
Tommasi S; Mangia A; Lacalamita R; Bellizzi A; Fedele V; Chiriatti A; Thomssen C; Kendzierski N; Latorre A; Lorusso V; Schittulli F; Zito F; Kavallaris M; Paradiso A
Int J Cancer; 2007 May; 120(10):2078-85. PubMed ID: 17285590
[TBL] [Abstract][Full Text] [Related]
10. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
Mozzetti S; Ferlini C; Concolino P; Filippetti F; Raspaglio G; Prislei S; Gallo D; Martinelli E; Ranelletti FO; Ferrandina G; Scambia G
Clin Cancer Res; 2005 Jan; 11(1):298-305. PubMed ID: 15671559
[TBL] [Abstract][Full Text] [Related]
11. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer.
Egawa C; Miyoshi Y; Takamura Y; Taguchi T; Tamaki Y; Noguchi S
Int J Cancer; 2001 Jul; 95(4):255-9. PubMed ID: 11400119
[TBL] [Abstract][Full Text] [Related]
13. beta-Tubulin III mRNA expression and docetaxel sensitivity in non-small cell lung cancer.
Wang LF; Yin HT; Qian XP; Wei J; Zhao Y; Yu LX; Liu BR
Clin Invest Med; 2009 Dec; 32(6):E278. PubMed ID: 20003833
[TBL] [Abstract][Full Text] [Related]
14. Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling.
Zembutsu H; Suzuki Y; Sasaki A; Tsunoda T; Okazaki M; Yoshimoto M; Hasegawa T; Hirata K; Nakamura Y
Int J Oncol; 2009 Feb; 34(2):361-70. PubMed ID: 19148470
[TBL] [Abstract][Full Text] [Related]
15. Comparison of beta-tubulin mRNA and protein levels in 12 human cancer cell lines.
Hiser L; Aggarwal A; Young R; Frankfurter A; Spano A; Correia JJ; Lobert S
Cell Motil Cytoskeleton; 2006 Jan; 63(1):41-52. PubMed ID: 16362954
[TBL] [Abstract][Full Text] [Related]
16. Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.
Pentheroudakis G; Batistatou A; Kalogeras KT; Kronenwett R; Wirtz RM; Bournakis E; Eleftheraki AG; Pectasides D; Bobos M; Papaspirou I; Kamina S; Gogas H; Koutras AK; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2011 May; 127(1):179-93. PubMed ID: 21390496
[TBL] [Abstract][Full Text] [Related]
17. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
[TBL] [Abstract][Full Text] [Related]
18. Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.
Zhao HY; Huang H; Hu ZH; Huang Y; Lin SX; Tian Y; Lin TY
Anticancer Drugs; 2012 Jun; 23(5):534-42. PubMed ID: 22481060
[TBL] [Abstract][Full Text] [Related]
19. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers.
Tham YL; Gomez LF; Mohsin S; Gutierrez MC; Weiss H; Hilsenbeck SG; Elledge RM; Chamness GC; Osborne CK; Allred DC; Chang JC
Breast Cancer Res Treat; 2005 Dec; 94(3):279-84. PubMed ID: 16261403
[TBL] [Abstract][Full Text] [Related]
20. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
Zhang HL; Ruan L; Zheng LM; Whyte D; Tzeng CM; Zhou XW
Lung Cancer; 2012 Jul; 77(1):9-15. PubMed ID: 22306125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
